 HOUSTON, Aug. 07, 2020 GLOBE NEWSWIRE -- Bio-Path Holdings, Inc., NASDAQ: BPTH, a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, August 14, 2020 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2020 and to provide a business overview. To access the live conference call, please call 844 815-4963 domestic or 210 229-8838 international at least five minutes prior to the start time and refer to conference ID 3237808. A live audio webcast of the call will also be available on the Events section of the Companys website, An archived webcast will be available on the Bio-Path website approximately two hours after the event. About Bio-Path Holdings, Inc.Bio-Path is a biotechnology company developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Paths lead product candidate, prexigebersen BP1001, targeting the Grb2 protein, is in a Phase 2 study for blood cancers and prexigebersen-A, a drug product modification of prexigebersen, is under consideration by the FDA to commence Phase 1 studies in solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, where it will be evaluated in lymphoma and solid tumors clinical studies.For more information, please visit the Companys website at Contact Information:InvestorsWill OConnor Stern Investor Relations 212-362-1200 Doug Morris Investor Relations Bio-Path Holdings, Inc. 832-742-1369 